Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373Posted by On

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the GLP Safety and Toxicology Program of EB-373 is proceeding as planned thus far with favorable results. In-life portion of the repeat dose toxicology studies have been completed, and the results are being an

Source link


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.